AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01705574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTV
Description: 100 mg tablet administered orally with food once daily
Study NCT01705574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FTC/TDF
Description: 200/300 mg tablet administered orally with food once daily
Study NCT03288207 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Bluetooth-enabled glucometer
Description: Bluetooth-enabled glucometer
Study NCT01705574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TDF
Description: 200/300 mg tablet administered orally with food once daily
Study NCT03288207 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Bluetooth-enabled scale
Description: Bluetooth-enabled scale
Study NCT03288207 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Global Positioning System (GPS) Device
Description: Global Positioning System (GPS) Device
Study NCT03288207 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Step it Up mobile app
Description: Step it Up mobile app
Study NCT01705574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E/C/F/TDF Placebo
Description: Tablet administered orally with food once daily
Study NCT01705574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATV Placebo
Description: Tablet administered orally with food once daily
Study NCT01705574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTV Placebo
Description: Capsule administered orally with food once daily
Study NCT01705574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TDF Placebo
Description: Tablet administered orally with food once daily
Study NCT04562896 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom Carbon Fiber Dynamic Orthosis (CDO)
Description: The custom carbon fiber dynamic orthoses will consist of a semi-rigid foot plate, a posterior carbon fiber strut, and a proximal cuff below the knee.
Study NCT01705574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Description: 150/150/200/10 mg FDC tablet administered orally with food once daily
Study NCT01660594 — intervention group
Intervention type: OTHER
Intervention: CT calcium scoring
Description: CT Calcium scoring was performed in the patients as an imaging test in addition to the traditional assessment on the same day of patients attending the chest pain clinic on the first visit. This was performed with standard protocol and the absolute calcium score was calculated.
Study NCT00294047 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix
Description: Subjects were planned to receive three doses of the study vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
Study NCT00294047 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Subjects were planned to receive three doses of the control vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
Study NCT01066598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 IV weekly X 4 doses + Prednisone 1 mg/kg/d
Study NCT03649763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: lidocaine 1%, distal ( ulnar and medial nerve): 6ml/nerve , 12m total
Study NCT03649763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine 0.5%,distal ( ulnar and medial nerve): 6ml/nerve , 12m total
Study NCT03649763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: lidocaine 1%, distal and proximal ( ulnar and medial nerve): 3ml/nerve , 12m total
Study NCT04584749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Iv
Description: 2% lidocaine or 0.9% physiological saline will be used as placebo, and it will be administered as a bolus during anesthetic induction equivalent to 1.5 mg / kg of lidocaine. After induction, an intravenous infusion will be started at 0.1 ml / kg / h of the study preparation, equivalent to 2mg / kg / h of lidocaine.~20 ml syringe for induction and two 50 ml syringes for anesthetic maintenance containing 2% Lidocaine .
Study NCT04584749 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine Iv
Description: 2% lidocaine or 0.9% physiological saline will be used as placebo, and it will be administered as a bolus during anesthetic induction equivalent to 1.5 mg / kg of lidocaine. After induction, an intravenous infusion will be started at 0.1 ml / kg / h of the study preparation, equivalent to 2mg / kg / h of lidocaine.~20 ml syringe for induction and two 50 ml syringes for anesthetic maintenance containing 2% Lidocaine .
Study NCT01420978 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CSF Diversion
Description: CSF drainage
Study NCT01420978 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CSF Diversion
Description: CSF drainage
Study NCT04626778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peroxyl Mouthwash
Description: Mouthwash
Study NCT04626778 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Mouthwash
Description: Mouthwash
Study NCT03073057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol
Description: 2 inhalations as a single dose
Study NCT03073057 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Charcoal
Study NCT03073057 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Charcoal
Study NCT03073057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort Turbuhaler
Description: 2 inhalations as a single dose
Study NCT02011763 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Avaxim 80U Pediatric: Inactivated Hepatitis A Virus
Description: 0.5 mL, Intramuscular (2 injection 6 months apart)
Study NCT01732211 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD 0360324
Description: 100 mg Q2W or 150 mg Q2W via intravenous infusion based on protocol determined dose escalation/de-escalation criteria; 12 weeks Active Therapy;
Study NCT01732211 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline for injection
Description: normal saline Q2W via intravenous infusion for 12 weeks
Study NCT01319370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minoxidil
Description: 1 g of 5% Minoxidil topical foam twice daily over 24 weeks in double-blinded phase and further 80 weeks in open-label-phase
Study NCT01319370 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle of 5% Minoxidil topical foam
Description: 1 g of vehicle topical foam twice daily over 24 weeks in double-blinded phase and further 80 weeks in open-label-phase
Study NCT02843607 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryosurgery
Description: Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
Study NCT02843607 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryosurgery
Description: Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
Study NCT02843607 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK immunotherapy
Description: Natural killer cell (each treatment: about 10 billion cells transfusion in 3 times, i.v.)
Study NCT00731536 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study. Medical records of patients with the diagnosis of HSTCL in the PALGA database will be analyzed.
Study NCT02159404 — intervention group
Intervention type: BIOLOGICAL
Intervention: Immunotherapy
Study NCT03338023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2963016
Description: Administered SC
Study NCT03338023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lantus®
Description: Administered SC
Study NCT03338023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: Administered SC
Study NCT03338023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered SC
Study NCT01168180 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Thai massage
Description: The participants will receive thirty minutes session of traditional Thai massage onto the scapular region for 9 sessions over a period of 3 weeks
Study NCT01168180 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound therapy and hot pack
Study NCT02659228 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: EEG recording
Description: EEG recording with anesthetic (DIPRIVAN)
Study NCT02659228 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EEG recording
Description: EEG recording with anesthetic (DIPRIVAN)
Study NCT02659228 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG recording
Description: EEG recording with anesthetic (DIPRIVAN)
Study NCT02659228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthetics, Intravenous
Description: The participant will receive an intravenous infusion of propofol (DIPRIVAN Injectable Emulsion USP 1%, AstraZeneca).
Study NCT03489525 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose Escalation, MEDI2228, ADC (antibody drug conjugate)
Description: Single agent MEDI2228 will be administered to adult subjects with R/R MM. The study aims to evaluate up to 9 planned, sequentially ascending main dose levels
Study NCT03489525 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose Expansion, MEDI2228, ADC (antibody drug conjugate)
Description: Adult subjects with R/R MM with measurable disease will be enrolled in the dose-expansion cohort at the dose selected for evaluation in the dose-expansion phase.
Study NCT02643979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: 100mg of Propofol
Study NCT02643979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: 1mL of saline
Study NCT01189773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen and codeine
Description: ibuprofen: 10 mg/kg (max = 600 mg), codeine: 1 mg/kg (max = 60 mg)
Study NCT01189773 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ibuprofen and codeine
Description: ibuprofen: 10 mg/kg (max = 600 mg), codeine: 1 mg/kg (max = 60 mg)
Study NCT01835756 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Erchonia MLS
Description: The Erchonia® MLS contains 10 independent diodes, each emitting 17 milliwatts (mW), 635 nanometers (nm) of red laser light. The Erchonia MLS is applied to the lower back and hips area for 15 minutes per treatment administration, 6 times across 3 weeks, 2 times per week.
Study NCT03650504 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Above Artery Catheter Placement
Description: Nerve catheter placed between superficial femoral artery and sartorial muscle
Study NCT03650504 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Between Artery and Vein Placement
Description: Nerve catheter placed between superficial femoral artery and femoral vein
Study NCT02639676 — intervention group
Intervention type: OTHER
Intervention: Diffusion Lung Capacity (DLCO), Vascular Challenge, Video Imaging, Specimen Collections
Study NCT00987415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: allopurinol
Description: Allopurinol 300 mg daily for one week, then 600 mg daily to complete 24 weeks.
Study NCT00987415 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: Matching placebo 300 mg daily for one week, then 600 mg daily to complete 24 weeks.
Study NCT00795730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSA-789
Study NCT00795730 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00575679 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief motivational interview
Description: The brief motivational interview is a non-confrontational, patient-centered discussion between a counselor (e.g., social worker, nurse, physician, or psychologist) and an at-risk individual during which the individual's motivation and confidence to change health-related behaviors are explored.
Study NCT02320578 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D Laparoscopy
Description: 3D Laparoscopy approach
Study NCT02320578 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Laparoscopy
Description: Standard laparoscopy approach
Study NCT02509962 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Slow sodium tablets
Description: 6 g sodium chloride per day over 14 days
Study NCT02070432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUZ11
Description: LUZ11 i.v. administration followed by laser light irradiation
Study NCT03603132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hetrombopag Olamine
Description: 7.5mg in each cycle
Study NCT00322114 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lycopene
Description: Given orally
Study NCT00322114 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT01532661 — intervention group
Intervention type: OTHER
Intervention: observational study
Description: data collected by investigators
Study NCT05821543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin+sibutramine
Description: 1 tablet (850 mg + 10 mg) once per day in the morning, without chewing and followed with a glass of water, during meals, for 180 days. At Visit 3 (Day 30 ± 1), in the absence of a 2 kg weight loss compared to Visit1 (Day 1), the zero dose was increased to 1 tablet (850 mg + 15 mg)
Study NCT05821543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sibutramine+ microcrystalline cellulose
Description: 1 capsule (10 mg + 158.5 mg) once per day in the morning, without chewing and followed with a glass of water, during meals for, 180 days.At Visit 3 (Day 30 ± 1), in the absence of a 2 kg weight loss compared to Visit 1 (Day 1), the zero dose was increased to 1 capsule (15 mg + 153,5 mg)
Study NCT03469310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen 500Mg Cap
Description: non-narcotic medication first with narcotic as second choice
Study NCT01835756 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Laser
Description: The Placebo Laser has the same appearance and administration application as the Erchonia MLS but does not emit any therapeutic light.
Study NCT02000037 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IR Reflexotherapy
Description: 18 IR reflexotherapy sessions :~* Once a week for 12 weeks at the beginning of the study~* Once a week for 3 weeks, 9 months after the beginning of the study~* Once a week for 3 weeks, 15 months after the beginning of the study
Study NCT02000037 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary care
Description: Dietary consultation 1, 2, 3, 6, 9, 12, 15 and 18 months after the beginning of the study
Study NCT03469310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tylenol #3 Oral Tablet
Description: Narcotic medication first
Study NCT03469310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: non-narcotic medication first with narcotic as second choice
Study NCT03233048 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ORBERA™ Intragastric Balloon
Description: The balloon will be inserted into the stomach and inflated, and will remain in place for 6 months, after which the device will be removed.
Study NCT03940885 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinea plane block group
Description: Which will receive ultrasound-guided erector spinea plane block bilaterally and the local anesthetic injected will be total volume 25 ml on each side consisting of 15ml of 0.5% plus 5 ml 2% lidocaine HCL plus 5 ml saline
Study NCT03940885 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus abdominis plane block
Description: Which will receive ultrasound-guided Transversus Abdominis plane block bilaterally and the local anesthetic used will be total volume 25 ml on each side consisting of 15ml of 0.5% plus 5 ml 2% lidocaine HCL plus 5 ml saline
Study NCT03940885 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: this group will receive only standard general anesthesia
Study NCT03845283 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Behavioral Weight Loss Program
Description: A self-guided, online program that helps participants reduce excess calories and gradually increase physical activity.
Study NCT02000037 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary care
Description: Dietary consultation 1, 2, 3, 6, 9, 12, 15 and 18 months after the beginning of the study
Study NCT00005774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Early surfactant
Description: Early surfactant followed by extubation within 30 minutes and application of continuous positive airway pressure (CPAP)
Study NCT03845283 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Intervention
Description: An program designed to help participants gradually increase their physical activity and maintain an active lifestyle. The program encourages bouts of moderate-to-vigorous physical activity. Participants in this group will receive a Fitbit Versa to help them monitor their physical activity that they will be advised to wear daily. Participants will receive brief (5-10 minute) lessons weekly for the first 3 months and monthly for the last 3 months.
Study NCT03845283 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bite Counter
Description: Participants will receive a Bite Counter device to help them monitor and reduce their within-meal consumption. Participants will be asked to wear the device daily.
Study NCT03845283 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: This program allows participants to practice behavioral weight loss skills using a virtual reality system compatible with their home device. This program helps patients practice these skills in the following artificial settings: at home, at work, at the gym, and at a party. Each participant will be asked to play through each scene at least once during their participation, though they are encouraged to use the program regularly.
Study NCT03845283 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Meetings
Description: Participants will attend virtual meetings using their own device. Each virtual meeting focuses on a specific topic that will help patients lose weight. Participants are asked to virtually attend at least 6 meetings during their participation. There is no limit to how many they can attend. The meeting topics will rotate and repeat on a schedule.
Study NCT01309516 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Complex Intervention
Description: This 12 session Multimodal Psychosocial Intervention will include a supportive component, an educational component, psychosocial component and a parenting programme.
Study NCT02756871 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: online guided self-help intervention for perfectionism
Description: CBT based online guided self-help intervention for perfectionism based on CBT manual for treatment of perfectionism, Cognitive Behavioural Treatment of Perfectionism by Sarah Egan, Tracy Wade, Roz Shafran and Martin Antony
Study NCT00005774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard practice
Description: Surfactant according to current center practice, only after initiation of mechanical ventilation.
Study NCT01668537 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LF formulation of IMVAMUNE®
Study NCT01668537 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FD formulation of IMVAMUNE®
Study NCT03780725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754111
Description: Solution for infusion
Study NCT03780725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [89Zr]Zr-BI 754111
Description: Solution for infusion
Study NCT03780725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754091
Description: Solution for infusion
Study NCT04046653 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Allin
Description: Dietary supplement
Study NCT04046653 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sulforaphane
Description: Dietary supplement
Study NCT04046653 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dietary supplement
Study NCT04046653 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dietary supplement
Study NCT00112853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Description: Given orally
Study NCT00112853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given orally
Study NCT04073277 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCF-N-treated needles
Description: The SCF-N-treated needles were used for acupuncture at LI 4 (Hegu) and LI 11 (Quchi) acupoints in the experimental groups..